China’s biotech boom: why the nation must collaborate to stay ahead
Summary
China has moved from a follower in biomedical research to a global powerhouse in drug development, manufacturing and clinical-trial capacity. The country now supplies a large share of active pharmaceutical ingredients, developed more than 1,250 new drugs in 2024, and accounts for roughly one-fifth of global commercial clinical trials. Despite these gains, growing geopolitical tensions and tighter foreign scrutiny have prompted calls within China to build a closed, self-contained biotech ecosystem. The authors argue this would be counterproductive: biological innovation depends on open collaboration, diverse patient cohorts and shared standards — and isolation would harm China and global health.
Key Points
- China now supplies an estimated 70–95% of the global supply chain for many essential active pharmaceutical ingredients.
- In 2024 Chinese biotech firms developed over 1,250 new drugs, nearing the US total (≈1,440).
- China’s share of commercial clinical trials rose from ~9% in 2018 to about 20% in 2023, aided by large hospital networks and faster regulatory pathways.
- Regulatory reforms since 2015 and the National Reimbursement Drug List have made China attractive for early-stage trials but have also imposed steep price negotiations (average negotiated discount ~63% in 2024).
- Calls for a ‘closed loop’ domestic biotech ecosystem (driven by security concerns and policy directives in 2025) risk slowing scientific progress and reducing access to medicines globally.
- China still lags the US and EU in fundamental research, representation in high-impact journals, and in funding to sustain high-risk early-stage science.
- International trust, intellectual-property concerns and immature capital markets remain obstacles to China becoming fully self-sufficient.
Content summary
The article traces the forces behind China’s rapid rise in biotech: decades of manufacturing capacity, regulatory modernisation from 2015 onwards, large participant pools for trials, and a growing workforce trained in drug discovery. These strengths underpin China’s role in global manufacturing and early-phase drug development, particularly in oncology and immunology.
However, geopolitical pressures — illustrated by new US restrictions and a 2025 State Council push to prioritise domestic procurement — have encouraged some Chinese stakeholders to contemplate an inward-focused, secure biotech ecosystem. The authors warn that biology is less amenable to autarky than electronics: advances rely on open exchange of ideas, international cohorts and shared standards. They note inefficiencies in China’s highly competitive domestic market, a focus on incremental improvements rather than novel mechanisms, and shortfalls in capital to carry drugs from discovery through to commercialization.
Context and relevance
This commentary is important for policymakers, industry leaders and researchers. It highlights how the global drug-development ecosystem is interdependent: supply-chain dominance in manufacturing does not replace the need for cross-border collaboration in research, trials and regulation. Decisions to decouple will affect medicine availability, the pace of innovation, and international scientific trust.
Why should I read this?
Short version — if you care about where your medicines come from, how fast new treatments get developed, or the geopolitics shaping healthcare, this is worth five minutes. The piece explains why fencing off China’s biotech scene would be a false economy and spells out the real trade-offs between security-driven isolation and the gains from working together.
Author style
Punchy: the authors cut through the hype to say collaboration, not isolation, will best sustain innovation and global access to medicines. If you follow biotech, policy or pharma markets, their argument matters — and skipping the details would leave you missing key policy levers and risks.